A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.

Trial Profile

A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms MCL-004
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 24 Jan 2017 Status changed to completed.
    • 06 Dec 2016 Status changed from recruiting to active, no longer recruiting,according to the results published at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top